Biogen Inc. (BIIB, Financial), Regeneron Pharmaceuticals Inc. (REGN, Financial), Canon Inc. (CAJ, Financial), and Annaly Capital Management Inc. (NLY, Financial) have declined to their three-year lows.
Biogen Inc. (BIIB, Financial) declined to $224.57
The prices of Biogen Inc. (BIIB, Financial) shares have declined to $224.57 on Sept. 6, which is only 3.9% above the 3-year low of $215.78.
Biogen Inc. is an American international biotechnology company specializing in the research, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases. Some of the products of the company include Alprolix, Avonex, Eloctate, Fampyra and Gazyva.
Biogen Inc. has a market cap of $41.42 billion; its shares were traded around $224.57 with a price-earnings ratio of 8.36 and P/S ratio of 3.13. Biogen Inc. had an annual average earnings growth of 22.70% over the past 10 years.
On July 23 Biogen Inc. reported financial results for the second quarter of 2019. Total revenues for the quarter were $3.6 billion, an 8% increase compared to the same quarter prior year. GAAP net income and diluted earnings per share for the quarter was $1.5 billion and $7.85, respectively.
Regeneron Pharmaceuticals Inc. (REGN, Financial) declined to $292.00
The prices of Regeneron Pharmaceuticals Inc. (REGN, Financial) shares have declined to $292.00 on Sept. 6, which is only 4.3% above the 3-year low of $279.39.
Regeneron Pharmaceuticals Inc. is an American biotechnology company. Originally, the company focused on neurotrophic factors and their regenerative capabilities but has since branched out into the research of cytokine and tyrosine kinase receptors. The company is a component of both the Nasdaq-100 and S&P 500.
Regeneron Pharmaceuticals Inc. has a market cap of $32.07 billion; its shares were traded around $292.00 with a price-earnings ratio of 16.23 and price-sales ratio of 4.66. Regeneron Pharmaceuticals Inc. had an annual average earnings growth of 29.40% over the past 5 years.
On Aug. 28 Regeneron Pharmaceuticals Inc. announced that the U.S. District Court for the District of Delaware has ruled in the company’s favor and found that Amgen’s asserted patient claims for antibodies targeting PCSK9 are invalid based on lack of enablement. The ruling overturned portions of an earlier jury verdict upholding the validity of three claims.
Canon Inc. (CAJ, Financial) declined to $26.08
The prices of Canon Inc. (CAJ, Financial) shares have declined to $26.08 on Sept. 6, which is only 2.3% above the 3-year low of $25.49.
Canon Inc. is a Japanese international corporation focusing on the manufacture of imaging and optical products. Some of the company’s products include cameras, camcorders, photocopiers, steppers, and computer printers. The company has a primary listing on the Tokyo Stock Exchange and a secondary listing on the New York Stock Exchange. The company is also a component of the TOPIX Core 30.
Canon Inc. has a market cap of $27.81 billion; its shares were traded around $26.08 with a price-earnings ratio of 16.30 and price-sales ratio of 0.80. The trailing 12-month dividend yield of Canon Inc. stocks is 5.65%. The forward dividend yield of Canon Inc. stocks is 5.65%. Canon Inc. had an annual average earnings growth of 0.10% over the past 10 years.
On Sept. 5 Canon Inc. announced that three of its products, the Océ Colorado 1650 graphic printer, Océ Arizona 1380 printer, and Océ Touchstone Software have won the 2019 Specialty Graphic Imaging Association “Product of the Year” Awards. These awards are given out to acknowledge products of outstanding print quality, versatility, productivity and ease of use.
Annaly Capital Management Inc. (NLY, Financial) declined to $8.31
The prices of Annaly Capital Management Inc. (NLY, Financial) shares have declined to $8.31 on Sept. 6, which is only 2.9% above the 3-year low of $8.07.
Annaly Capital Management Inc. is an American mortgage real estate investment trust. The company borrows money via short term repurchase agreements and reinvests the proceeds in asset backed securities. The company generates profits from the net interest spread between the interest it earns from assets and borrowing costs.
Annaly Capital Management Inc. has a market cap of $12.1 billion; its shares were traded around $8.31 . The trailing 12-month dividend yield of Annaly Capital Management Inc. stocks is 11.18%. The forward dividend yield of Annaly Capital Management Inc. stocks is 11.95%.
On Aug. 14 Annaly Capital Management Inc. announced that the company’s Board of Directors has declared a Series D Preferred Stock cash dividend of $0.46875 per share of Series D Preferred Stock. The Board of Directors has also declared a Series F Preferred Stock cash dividend of $0.434375 per share of Series F Preferred Stock. The Board of Directors has also declared similar dividends on the company’s Series G and Series I Preferred Stock. These dividends will be payable on Sept. 30 to shareholders of record at the close of business on Sept. 3.
Disclosure: I do not own stock in any of the companies mentioned in the article.
